Vaccine recommendations by medical risk condition (ATAGI & NIP funding)

Select one or more conditions to see ATAGI’s recommendation and NIP funding status for each vaccine, then copy a summary for the record. Based on the Department of Health table (August 2026).

📋 Source: Australian Government Department of Health, Disability and Ageing — Immunisation recommendations for people with certain medical risk conditions (published through the Australian Immunisation Handbook; last updated August 2026). Reviewed by AskMyGP 1 October 2026. General information, not medical advice.

Read first. (1) COVID-19 funding changed on 1 October 2026 — this August table describes COVID-19 vaccines as funded under emergency measures, so funding is deliberately not shown here; see the COVID-19 guide. (2) Age criteria apply: flu from 6 months; RSV (older adults) from 60 years; COVID-19 from 18 years with severe immunocompromise, 50+ for Aboriginal and Torres Strait Islander adults, 65+ for non-Indigenous adults. (3) The table lists example conditions — similar conditions can be included on clinical judgement, and it does not cover doses that might be considered after an individual risk–benefit discussion.

Find your condition

0 selected

Full table

R (F) = recommended by ATAGI and funded; R (NF) = recommended but not funded; NR = not recommended on this basis. Letters refer to the notes below the table. Scroll sideways on a phone.

Vaccine recommendations by medical risk condition (Department of Health, August 2026)
Medical risk condition	Influenza^a	COVID-19^a	RSV vaccine^a	RSV (infants & young children)^b	Pneumococcal^c	Hib	Meningococcal	Hepatitis A	Hepatitis B	HPV	Zoster	Mpox
Cardiac disease
Congenital heart disease	R (F)	R (F)	R (NF)	R (NF)^d	R (F)^e	NR	NR	NR	NR	NR	NR	NR
Congestive heart failure	R (F)	R (F)	R (NF)	NR	R (F)^e	NR	NR	NR	NR	NR	NR	NR
Coronary artery disease	R (F)	R (F)	R (NF)	NR	R (F)^e	NR	NR	NR	NR	NR	NR	NR
Chronic respiratory conditions
Suppurative lung disease	R (F)	R (F)	R (NF)	NR	R (F)	NR	NR	NR	NR	NR	NR	NR
Bronchiectasis	R (F)	R (F)	R (NF)	NR	R (F)	NR	NR	NR	NR	NR	NR	NR
Cystic fibrosis	R (F)	R (F)	R (NF)	R (NF)	R (F)	NR	NR	NR	NR	NR	NR	NR
Chronic obstructive pulmonary disease and chronic emphysema	R (F)	R (F)	R (NF)	NR	R (F)	NR	NR	NR	NR	NR	NR	NR
Severe asthma (requiring frequent medical consultations or the use of multiple medicines)	R (F)	R (F)	R (NF)	NR	R (NF)	NR	NR	NR	NR	NR	NR	NR
Chronic lung disease in preterm infants	NR	NR	NR	R (NF)^f	R (F)	NR	NR	NR	NR	NR	NR	NR
Interstitial and fibrotic lung disease	NR	NR	NR	NR	R (NF)	NR	NR	NR	NR	NR	NR	NR
Immunocompromising conditions
Immunosuppressive therapy	R (F)	R (F)^g	R (NF)	R (NF)^h	R (NF)	NR	NR	NR	NR	R (F)	R (F)^g	NR
Inborn errors of immunity, including primary immunodeficiency disordersⁱ	R (F)	R (F)	R (NF)	R (NF)	R (F)	NR	NR	NR	NR	R (F)	R (F)	NR
Solid organ transplant	R (F)	R (F)	R (NF)	R (NF)	R (F)	NR	NR	R (NF)^j	R (NF)	R (F)	R (F)	NR
Haematopoietic stem cell transplant	R (F)	R (F)	R (NF)	R (NF)	R (F)	R (NF)	R (NF)	NR	R (NF)	R (F)	R (F)	NR
CAR-T cell therapy	R (F)	R (F)	R (NF)	R (NF)	NR	NR	NR	NR	NR	NR	R (F)	NR
Non-haematological malignancies receiving chemotherapy or radiotherapy (currently or anticipated)	R (F)	R (F)^k	R (NF)	R (NF)	R (NF)	NR	NR	NR	NR	R (F)	R (F)^k	NR
Haematological malignancy	R (F)	R (F)^l	R (NF)	R (NF)	R (F)	NR	NR	NR	NR	R (F)	R (F)	NR
HIV infection	R (F)	R (F)^m	R (NF)	R (NF)ⁿ	R (F)	NR	R (NF)	NR	R (NF)	R (F)^o	R (F)^m	R (NF)^p
Asplenia or splenic dysfunction	R (F)	R (F)	R (NF)	NR	R (F)	R (F)	R (F)	NR	NR	NR	NR	NR
Complement deficiency/ complement inhibitor treatment	NR	NR	NR	NR	NR	NR	R (F)	NR	NR	NR	R (NF)	NR
Haematological disorder
Sickle cell disease or other haemoglobinopathies	R (F)	R (F)	R (NF)	NR	R (F)	NR	NR	NR	NR	NR	NR	NR
Chronic metabolic disorder
Type 1 or 2 diabetes	R (F)	R (F)	R (NF)	NR	R (NF)	NR	NR	NR	NR	NR	NR	NR
Amino acid disorders	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Carbohydrate disorders	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Cholesterol biosynthesis disorders	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Fatty acid oxidation defects	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Lactic acidosis	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Mitochondrial disorders	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Organic acid disorders	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Urea cycle disorders	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Vitamin/cofactor disorders	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Porphyrias	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Chronic kidney disease
Chronic renal impairment – eGFR <30 mL/min (stage 4 or 5 disease)	R (F)	R (F)	R (NF)	NR	R (F)^q	NR	NR	NR	R (NF)	NR	R (F)^q	NR
Relapsing or persistent nephrotic syndrome	NR	NR	NR	NR	R (F)	NR	NR	NR	NR	NR	NR	NR
Chronic neurological condition
Hereditary and degenerative CNS diseases	R (F)	R (F)	R (NF)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR
Seizure disorders	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Spinal cord injuries	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Neuromuscular disorders	R (F)	R (F)	R (NF)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR
Conditions that impair respiratory or airway function	R (F)	R (F)	R (NF)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR
CSF leak (proven or presumptive)
Cochlear implants	NR	NR	NR	NR	R (F)	NR	NR	NR	NR	NR	NR	NR
Intracranial shunts	NR	NR	NR	NR	R (F)	NR	NR	NR	NR	NR	NR	NR
Chronic liver disease
Conditions with progressive deterioration of liver function for more than 6 months, including cirrhosis and other advanced liver diseases	R (NF)	R (F)	R (NF)	NR	R (F)	NR	NR	R (NF)	R (NF)	NR	NR	NR
Obesity
Obesity — body mass index ≥30 kg per m²	R (NF)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Chromosomal abnormality
Trisomy 21 or another genetic condition that increases the risk of severe disease	R (NF)	R (F)	NR	R (NF)	R (F)^e	NR	NR	NR	NR	NR	NR	NR
Other conditions
Developmental disability	NR	NR	NR	NR	NR	NR	NR	R (NF)	R (NF)	NR	NR	NR
Born to mothers who are surface antigen positive (hep B)	NR	NR	NR	NR	NR	NR	NR	NR	R (NF)	NR	NR	NR
Born to mothers who received anti-CD20 therapies (such as rituximab) during pregnancy	NR	NR	NR	R (NF)	R (NF)	NR	NR	NR	NR	NR	NR	NR
Prematurity (<37 weeks)	R (F)	NR	NR	R (NF)(<32 weeks)	R (F)^e(<28 weeks)	NR	NR	NR	R (NF)^r(<32 weeks)	NR	NR	NR
Previous episode of severe disease (antigen-specific)	NR	NR	NR	NR	R (F)	NR	NR	NR	NR	NR	NR	NR
Receipt of blood products	NR	NR	NR	R (NF)^s	NR	NR	NR	NR	R (NF)	NR	NR	NR
Medication use
Long-term aspirin therapy in children aged 5–10 years	R (F)	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Other substance use
Harmful use of alcohol^t	R (NF)	NR	NR	NR	R (NF)	NR	NR	NR	NR	NR	NR	NR
Smoking (current or in the immediate past)	R (NF)	NR	NR	NR	R (NF)	NR	R (NF)^u	NR	NR	NR	NR	NR
Intravenous drug use	NR	NR	NR	NR	NR	NR	NR	R (NF)	R (NF)	NR	NR	NR

Notes

a These vaccines are recommended for people with certain medical conditions. Similar conditions to those indicated may be included based on clinical judgement. Influenza (aged ≥6 months), RSV (aged ≥60 years) and COVID-19 (aged ≥18 years for severe immunocompromise, aged ≥50 years for Aboriginal and Torres Strait Islander adults and aged ≥65 years for non-Indigenous adults).
b RSV monoclonal antibody is recommended for children <24 months of age with certain medical conditions, irrespective of whether their mother received an RSV vaccine during pregnancy. It may be funded under state and territory programs.
c Pneumococcal vaccines are recommended for people with certain medical conditions. Cardiac and respiratory conditions that are similar to those indicated may be included based on clinical judgement.
d Hemodynamically significant congenital heart disease only.
e Funded under the NIP for children aged <5 years only.
f Chronic lung disease requiring ongoing oxygen or respiratory support.
g Funded under the NIP for B- and T-cell targeted monoclonal antibody therapies, some conventional immunosuppressive agents, some biologic therapies, immunomodulatory drugs, oral small molecule targeted therapies, immunosuppressive therapies to prevent organ rejection and some interleukin inhibitors. For more detail refer to the Australian Immunisation Handbook.
h Significant immunosuppression equivalent to conditions or treatments listed in the RSV chapter.
i Specific disease-based recommendations and funding may vary depending on the type of inborn error of immunity and which part of the immune system is affected. For more detail refer to the Australian Immunisation Handbook.
j Liver transplant recipients.
k Funded under the NIP for people with non-haematological cancers receiving chemotherapy only (i.e. not radiotherapy alone).
l Funded under the NIP for those treated with B- and T-cell targeted therapies and immunomodulatory drugs. For more detail refer to the Australian Immunisation Handbook.
m Funded under the NIP for HIV infection with a CD4+ cell count <200/µL.
n RSV monoclonal antibody is recommended for infants and children who have CD4+ count associated with severe immunocompromise (CD4+ cell count: <750/uL for infants aged <12 months and <500/uL for children aged ≥12 to <24 months).
o Funded under the NIP for people aged <26 years only.
p Mpox vaccination is recommended for people living with HIV if they are at risk of mpox exposure.
q Funded under the NIP for eGFR <15 mL/min only (including patients on dialysis).
r Includes low-birthweight infants (<2000 g), regardless of gestational age.
s For infants who have undergone exchange transfusion at birth.
t Defined as the consumption of on average ≥100 g of alcohol (10 Australian standard drinks) per week or ≥40 g of alcohol (4 Australian standard drinks).
u Recommended for smokers aged <25 years.

Sources & disclaimer

Australian Government Department of Health, Disability and Ageing — Immunisation recommendations for people with certain medical risk conditions (August 2026), via the Australian Immunisation Handbook.
Australian Immunisation Handbook — Table. Example conditions associated with increased risk of severe outcomes from COVID-19 (last updated 30 September 2026).
Australian Immunisation Handbook — Table. Risk conditions for pneumococcal vaccination and eligibility for NIP funding and the Department of Health 2026 Influenza Vaccination program advice (February 2026): the pneumococcal and influenza funding in the table above was checked against both in October 2026 and is consistent.

Reference for health professionals, not clinical advice for an individual patient; funding and recommendations change — confirm in the Handbook and the NIP schedule.

Patient version (share with patients) → Vaccination clinical tool → GP vaccine updates → Flu vaccine funding →